Advertisement

Bortezomib-containing therapy in Japanese children with relapsed acute lymphoblastic leukemia

  • Daisuke HasegawaEmail author
  • Yuri Yoshimoto
  • Shunsuke Kimura
  • Tadashi Kumamoto
  • Naoko Maeda
  • Junichi Hara
  • Atsushi Kikuta
  • Akiko Kada
  • Toshimi Kimura
  • Yuka Iijima-Yamashita
  • Akiko M. Saito
  • Keizo Horibe
  • Atsushi Manabe
  • Chitose Ogawa
Original Article
  • 65 Downloads

Abstract

Outcomes of children treated for relapsed acute lymphoblastic leukemia (ALL) remain poor. Bortezomib (BZM), a proteasome inhibitor, has shown promising activity against lymphoid malignancies. We conducted a phase I study to evaluate the safety and tolerability of multidrug chemotherapy including BZM in Japanese children with relapsed ALL. Three of five children with relapsed ALL enrolled in the study between November 2014 and April 2016 were evaluated. BZM (1.3 mg/m2) was administered on days 8, 11, 15, and 18 of multidrug induction chemotherapy. Pharmacokinetic studies were performed. Age at study entry was 5, 7, and 7 years old, respectively. Two patients had hyperdiploid B-precursor ALL, and one had T cell ALL. Although all patients experienced grade 3–4 hematologic toxicity and grade 3 elevation of aminotransferases, no dose-limiting toxicities were observed. The maximum tolerated dose was defined as 1.3 mg/m2. Peripheral neuropathy and respiratory complications were not observed. Complete remission was achieved in all three patients. The mean maximum plasma concentration and area under the concentration–time curve was 74.0 ng/mL and 73.9 ng h/mL, respectively. Thus, adding BZM to 5-drug induction chemotherapy appears safe and well-tolerated in Japanese children with relapsed ALL.

Keywords

Bortezomib Combination chemotherapy Acute lymphoblastic leukemia Relapse Children 

Notes

Acknowledgements

This trial was supported by AMED under Grant number JP17ck0106110. We thank all the patients, families, and investigators who participated in this trial.

Author contributions

DH collected samples and data, analyzed data and wrote the manuscript; YY, SK, and TD collected samples and data and analyzed data; NM, JH, AtK, and KH analyzed data and gave conceptual advice; AkK performed the statistical analysis and wrote the manuscript. TK performed pharmacokinetic analyses; YIY performed minimal residual disease analyses; AMS performed data management and monitoring during this trial; AM analyzed data, gave conceptual advice, and wrote the manuscript; CO contributed to the conception and design of this study. All authors have read and approved the final version of the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

References

  1. 1.
    Horibe K, Saito AM, Takimoto T, Tsuchida M, Manabe A, Shima M, et al. Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006–2010): based on registry data from the Japanese Society of Pediatric Hematology. Int J Hematol. 2013;98:74–88.CrossRefGoogle Scholar
  2. 2.
    Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373:1541–52.CrossRefGoogle Scholar
  3. 3.
    Goto H. Childhood relapsed acute lymphoblastic leukemia: biology and recent treatment progress. Pediatr Int. 2015;57:1059–66.CrossRefGoogle Scholar
  4. 4.
    Locatelli F, Schrappe M, Bernardo ME, Rutella S. How I treat relapsed childhood acute lymphoblastic leukemia. Blood. 2012;120:2807–16.CrossRefGoogle Scholar
  5. 5.
    Tallen G, Ratei R, Mann G, Kaspers G, Niggli F, Karachunsky A, et al. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol. 2010;28:2339–47.CrossRefGoogle Scholar
  6. 6.
    Messinger Y, Gaynon P, Raetz E, Hutchinson R, Dubois S, Glade-Bender J, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer. 2010;55:254–9.CrossRefGoogle Scholar
  7. 7.
    Messinger YH, Gaynon PS, Sposto R, van der Giessen J, Eckroth E, Malvar J, et al. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: therapeutic advances in childhood leukemia and lymphoma (TACL) study. Blood. 2012;120:285–90.CrossRefGoogle Scholar
  8. 8.
    Iguchi A, Cho Y, Sugiyama M, Terashita Y, Ariga T, Hosoya Y, et al. Bortezomib combined with standard induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia. Int J Hematol. 2017;106:291–8.CrossRefGoogle Scholar
  9. 9.
    van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia. 2007;21:604–11.CrossRefGoogle Scholar
  10. 10.
    van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257–317.CrossRefGoogle Scholar
  11. 11.
    Ogawa Y, Suzuki K, Sakai A, Evans PA, Hummel M, Lavender FL, et al. Phase I/II study of bortezomib-melphalan-prednisolone for previously untreated Japanese patients with multiple myeloma. Cancer Sci. 2013;104:912–9.CrossRefGoogle Scholar
  12. 12.
    Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC, et al. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children’s Oncology Group study. Clin Cancer Res. 2007;13:1516–22.CrossRefGoogle Scholar
  13. 13.
    Bertaina A, Vinti L, Strocchio L, Gaspari S, Caruso R, Algeri M, et al. The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood. Br J Haematol. 2017;176:629–36.CrossRefGoogle Scholar
  14. 14.
    Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24:3113–20.CrossRefGoogle Scholar
  15. 15.
    Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood. 2006;107:3492–4.CrossRefGoogle Scholar
  16. 16.
    Yoshizawa K, Mukai HY, Miyazawa M, Miyao M, Ogawa Y, Ohyashiki K, et al. Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization. Cancer Sci. 2014;105:195–201.CrossRefGoogle Scholar
  17. 17.
    Ogawa Y, Tobinai K, Ogura M, Ando K, Tsuchiya T, Kobayashi Y, et al. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Cancer Sci. 2008;99:140–4.Google Scholar
  18. 18.
    Eckert C, Henze G, Seeger K, Hagedorn N, Mann G, Panzer-Grümayer R, et al. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group. J Clin Oncol. 2013;31:2736–42.CrossRefGoogle Scholar
  19. 19.
    Hu X, Xu J, Sun A, Shen Y, He G, Guo F. Successful T-cell acute lymphoblastic leukemia treatment with proteasome inhibitor bortezomib based on evaluation of nuclear factor-κB activity. Leuk Lymphoma. 2011;52:2393–5.CrossRefGoogle Scholar
  20. 20.
    Horton TM, Whitlock JA, Lu X, O’Brien MM, Borowitz MJ, Devidas M, et al. Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children’s Oncology Group. Br J Haematol. 2019;186:274–85.Google Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  • Daisuke Hasegawa
    • 1
    Email author
  • Yuri Yoshimoto
    • 1
  • Shunsuke Kimura
    • 1
  • Tadashi Kumamoto
    • 1
    • 2
  • Naoko Maeda
    • 3
  • Junichi Hara
    • 4
  • Atsushi Kikuta
    • 5
  • Akiko Kada
    • 6
  • Toshimi Kimura
    • 7
  • Yuka Iijima-Yamashita
    • 6
  • Akiko M. Saito
    • 6
  • Keizo Horibe
    • 6
  • Atsushi Manabe
    • 1
  • Chitose Ogawa
    • 2
  1. 1.Department of PediatricsSt. Luke’s International HospitalTokyoJapan
  2. 2.Department of Pediatric OncologyNational Cancer Center HospitalTokyoJapan
  3. 3.Department of PediatricsNational Hospital Organization Nagoya Medical CenterNagoyaJapan
  4. 4.Department of Pediatric Hematology and OncologyOsaka City General HospitalOsakaJapan
  5. 5.Department of Pediatric OncologyFukushima Medical University HospitalFukushimaJapan
  6. 6.Clinical Research CenterNational Hospital Organization Nagoya Medical CenterNagoyaJapan
  7. 7.Department of PharmacyTokyo Women’s Medical University HospitalTokyoJapan

Personalised recommendations